文献速递肝胆胰外科

局部进展期胰腺癌新辅助化疗后海德堡三角清扫术的短期结局

[Short-term outcomes of the TRIANGLE operation after neoadjuvant chemotherapy in locally advanced pancreatic cancer].
PubMed 文献 · Zhonghua Wai Ke Za Zhi · 2024-01-01

本研究为回顾性病例系列分析,纳入2020年1月至2022年12月在南京医科大学第一附属医院胰腺中心接受新辅助化疗的103例局部进展期胰腺癌患者,其中26例(25.2%)行海德堡三角清扫胰腺癌切除术。结果显示R0切除率为61.5%(16/26),R1(1 mm)切除率为38.5%(10/26),术后总体并发症发生率为57.7%(15/26),围手术期无二次手术,1例患者术后第32天死亡。

要点

  • 局部进展期胰腺癌新辅助化疗后行海德堡三角清扫,R0切除率为61.5%(16/26)。
  • 术后总体并发症发生率为57.7%(15/26),B/C级胰瘘发生率为25.0%(6/24)。
  • 围手术期无二次手术,1例患者术后第32天因假性动脉瘤破裂死亡。

核心结论

  • 局部进展期胰腺癌患者新辅助化疗后按海德堡三角方案行胰十二指肠切除术,可能提高R0切除率,且未增加围手术期病死率或术后主要并发症发生率。

研究设计与样本

  • 本研究为回顾性病例系列分析,纳入2020年1月至2022年12月于南京医科大学第一附属医院胰腺中心接受新辅助化疗的103例局部进展期胰腺癌患者,其中26例(25.2%)行海德堡三角清扫胰腺癌切除术。

主要发现

  • 新辅助化疗后血清CA19-9下降92.3(40.1)%(范围:2.1%~97.7%),疗效评估为疾病稳定13例(50.0%)、部分缓解11例(42.3%)、完全缓解2例(7.7%)。
  • 手术方式为胰十二指肠切除术12例(46.2%)、胰体尾切除术12例(46.2%)、全胰切除术2例(7.7%)。
  • R0切除率为61.5%(16/26),R1(1 mm)切除率为38.5%(10/26);前切缘R1(1 mm)切除率为23.1%(6/26),后切缘为19.2%(5/26),断端切缘为12.5%(3/24),门静脉沟切缘为2/14,钩突切缘为1/12。
  • 术后总体并发症发生率为57.7%(15/26),B/C级胰瘘发生率为25.0%(6/24),胃排空延迟发生率为23.1%(6/26),切口并发症发生率为11.5%(3/26),术后出血发生率为7.7%(2/26),乳糜瘘发生率为7.7%(2/26),胆瘘发生率为3.8%(1/26)。
  • 围手术期(术后90 d内)无二次手术,1例患者术后第32天因胃十二指肠动脉残端假性动脉瘤破裂死亡;开始新辅助化疗后1年和3年总体生存率分别为95.8%和58.9%,术后1年和3年总体生存率分别为77.7%和57.8%。

临床怎么用

  • 作者认为,局部进展期胰腺癌患者新辅助化疗后按海德堡三角方案行胰十二指肠切除术,可能提高R0切除率,且未增加围手术期病死率或术后主要并发症发生率。

局限性

  • 本研究为回顾性病例系列分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the safety and efficacy of the TRIANGLE operation after neoadjuvant chemotherapy in locally advanced pancreatic cancer(LAPC). Methods: This study is a retrospective case series analysis. Between January 2020 and December 2022, a total of 103 patients were diagnosed as LAPC who underwent neoadjuvant chemotherapy at the Pancreas Center, the First Affiliated Hospital of Nanjing Medical University. Among them, 26 patients (25.2%) underwent the TRIANGLE operation. There were 15 males and 11 females,with a age of (59±7) years (range: 49 to 74 years). The pre-treatment serum CA19-9(M(IQR)) was 248.8(391.6)U/ml (range: 0 to 1 428 U/ml),and the serum carcinoembryonic antigen was 4.1(3.8)μg/L(range: 1.4 to 13.4 μg/L). The neoadjuvant chemotherapy regimens included: mFOLFIRINOX regimen in 6 cases(23.1%), GnP regimen in 14 cases(53.8%), and mFOLFIRINOX+GnP regimen in 6 cases(23.1%). The follow-up duration extended until June 2023 or until the occurrence of the patient's death or loss to follow-up. The Kaplan-Meier method was employed to estimate the 1-year and 3-year overall survival rates. Results: After neoadjuvant chemotherapy,CA19-9 levels decreased by 92.3(40.1)%(range:2.1% to 97.7%). Evaluation of the response to treatment revealed 13 cases(50.0%) of stable disease,11 cases(42.3%) of partial response,and 2 cases(7.7%) of complete response. The surgical operation consisted of 12 cases(46.2%) of pancreaticoduodenectomy,12 cases(46.2%) of distal pancreatectomy,and 2 cases(7.7%) of total pancreatectomy. Margin determination was based on the "standardised pathology protocol" and the "1 mm" principle. No R2 and R1(direct) resections were observed,while the R0 resection rate was 61.5%(16/26), and the R1(1 mm) resection rate was 38.5%(10/26).The R1(1 mm) resection rates for the anterior margin,posterior margin,transected margin,portal vein groove margin,and uncinate margin were 23.1%(6/26),19.2%(5/26),12.5%(3/24),2/14, and 1/12, respectively. The overall postoperative complication rate was 57.8%(15/26),with major complications including grade B/C pancreatic fistula 25.0%(6/24,excluding 2 cases of total pancreatectomy),delayed gastric emptying in 23.1%(6/26),wound complications 11.5%(3/26),postoperative hemorrhage 7.7%(2/26), chylous fistula 7.7%(2/26) and bile fistula 3.8%(1/26). No reoperation was performed during the perioperative period(<90 days). One patient died on the 32nd day postoperatively due to a ruptured pseudoaneurysm. A total of 25 patients were followed up,with a follow-up time of 21(24)months(range: 8 to 42 months). During the follow-up period,8 cases(32.0%) died due to tumor recurrence and metastasis,while 17 patients(68.0%) remained alive,including 11 cases of disease-free survival,5 cases of distant metastasis,and 1 case of local recurrence. The overall survival rates at 1- and 3-year after the initiation of neoadjuvant chemotherapy were 95.8% and 58.9%, respectively. The overall survival rates at 1- and 3-year after surgery were 77.7% and 57.8%, respectively. Conclusion: Performing pancreatoduodenectomy according to the Heidelberg triangle protocol in LAPC patients after neoadjuvant chemotherapy might increase the R0 resection rate without increasing perioperative mortality or the incidence of major postoperative complications. 目的: 探讨局部进展期胰腺癌(LAPC)转化治疗后行海德堡三角清扫的安全性和有效性。 方法: 本研究为回顾性病例系列研究。回顾性收集2020年1月至2022年12月于南京医科大学第一附属医院胰腺中心接受转化治疗的103例LAPC患者资料,将其中26例(25.2%)行海德堡三角清扫胰腺癌切除术的患者纳入研究。男性15例,女性11例,年龄(59±7)岁(范围:49~74岁)。治疗前CA19-9[M(IQR)]为248.8(391.6)U/ml(范围:0~1 428 U/ml),癌胚抗原为4.1(3.8)μg/L(范围:1.4~13.4 μg/L)。转化治疗方案包括mFOLFIRINOX方案(6例,23.1%)、GnP方案(14例,53.8%)、mFOLFIRINOX+GnP 方案(6例,23.1%)。随访时间截至2023年6月或患者死亡、失访。采用Kaplan-Meier法估算患者1年和3年总体生存率。 结果: 转化治疗后疗效评估,血清CA19-9下降92.3(40.1)%(范围:2.1%~97.7%)。疾病稳定13例(50.0%),部分缓解11例(42.3%),完全缓解2例(7.7%)。手术方式包括胰十二指肠切除术(12例,46.2%)、胰体尾切除术(12例,46.2%)、全胰切除术(2例,7.7%)。遵循标准化病理流程和“1 mm原则”,R0切除率为61.5%(16/26),R1(1 mm)切除率为38.5%(10/26)。各切缘R1(1 mm)切除率如下:前切缘23.1%(6/26),后切缘19.2%(5/26),断端切缘12.5%(3/24),门静脉沟切缘2/14,钩突切缘1/12。术后总体并发症发生率为57.7%(15/26),其中B、C级胰瘘发生率为25.0%(6/24),胃排空延迟发生率为 23.1%(6/26),切口并发症发生率为11.5%(3/26),术后出血发生率为7.7%(2/26),乳糜瘘发生率为7.7%(2/26),胆瘘发生率为3.8%(1/26)。围手术期(术后90 d内)无二次手术,1例患者术后第32天因胃十二指肠动脉残端假性动脉瘤破裂死亡。余25例患者获得随访,随访时间为21(24)个月(范围:8~42个月)。随访期间,8例(32.0%)患者因肿瘤复发转移死亡,17例(68.0%)存活,包括无瘤生存11例、远处转移5例、局部复发1例。开始转化治疗后1、3年总体生存率分别为95.8%、58.9%,术后1、3年总体生存率分别为77.7%、57.8%。 结论: LAPC转化治疗后行联合海德堡三角清扫胰腺癌切除术的R0切除率较高,围手术期病死率及术后主要并发症发生率未见明显升高,可能改善患者的远期生存。.

来源:Zhonghua Wai Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Xu D, Tu M, Zhang K, et al. [Short-term outcomes of the TRIANGLE operation after neoadjuvant chemotherapy in locally advanced pancreatic cancer]. Zhonghua Wai Ke Za Zhi. 2024. PMID: 38310383. doi:10.3760/cma.j.cn112139-20230615-000234

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。